What Testosterone Level Qualifies for TRT?

Most medical providers use 300 ng/dL as the threshold for testosterone replacement therapy qualification, though some require levels below 250 ng/dL. The American Urological Association uses total testosterone below 300 ng/dL on two separate early-morning blood draws, combined with symptoms, as its cutoff (2018 guideline, validity confirmed 2024); the Endocrine Society's 2018 guideline instead uses a harmonized lower limit of 264 ng/dL and requires unequivocally and consistently low morning values on separate days. Reference ranges vary by laboratory and age, so quote your own lab's range; on treatment, the AUA defines success as a level in the middle tertile of the normal range, about 450 to 600 ng/dL, and the Endocrine Society aims for the mid-normal range. However, qualification depends on more than numbers alone. Clinical symptoms like fatigue, reduced libido, muscle loss, and mood changes must accompany low lab values. Free testosterone matters mainly in the AUA's equivocal zone of 230 to 317 ng/dL total testosterone; the free testosterone cutoffs in published guidelines are 64 pg/mL (European Society of Endocrinology and European Academy of Andrology) and about 65 pg/mL (ISSAM), not 50. The American Urological Association emphasizes that symptomatic men with total testosterone consistently below 300 ng/dL represent the primary candidates for testosterone replacement therapy (AUA guideline, 2018, validity confirmed 2024).

Clinical Guidelines and Diagnostic Criteria

The two major U.S. guidelines set the parameters. The AUA's cutoff is a total testosterone below 300 ng/dL (Grade B evidence) on at least two separate early-morning blood draws (Grade A); the Endocrine Society's harmonized lower limit is 264 ng/dL, measured fasting in the morning on separate days, and it requires that the values be unequivocally and consistently low. This dual-testing requirement prevents misdiagnosis from temporary fluctuations caused by illness, stress, or sleep deprivation. Free testosterone measurements provide additional diagnostic value, particularly for men with normal total testosterone but symptoms of hypogonadism. Guideline free testosterone cutoffs sit at 64 to 65 pg/mL (ESE/EAA and ISSAM), and the AUA reserves free testosterone for men whose total testosterone falls in the 230 to 317 ng/dL equivocal zone. The combination of low free testosterone and clinical symptoms may qualify patients for treatment regardless of total testosterone values. Many clinics now incorporate complete hormone panels that evaluate luteinizing hormone, follicle-stimulating hormone, and sex hormone-binding globulin alongside testosterone measurements. This approach helps identify primary versus secondary hypogonadism and guides appropriate treatment selection.

Symptoms Required for TRT Qualification

Laboratory values alone cannot determine testosterone replacement therapy eligibility. The American Urological Association requires documented clinical symptoms that significantly impact quality of life alongside low testosterone levels. Primary symptoms include persistent fatigue unrelated to sleep disorders, reduced sexual desire and erectile dysfunction, decreased muscle mass despite regular exercise, and mood changes including depression or irritability. Secondary symptoms often include difficulty concentrating, reduced bone density, increased abdominal fat, and decreased body hair growth. Providers typically use standardized questionnaires like the Androgen Deficiency in Aging Males scale to quantify symptom severity and track treatment response. Age considerations play an important role in symptom evaluation. Some international guidelines set the bar higher than the AUA: ISSAM and the EAU use 12.1 nmol/L (about 350 ng/dL) and the ESE/EAA use 320 ng/dL, which is one reason two clinicians can read the same lab report differently. Some providers also consider peptide therapy options like Sermorelin for younger patients seeking natural hormone optimization.

Provider Variations and Treatment Thresholds

Different medical specialties apply varying criteria for testosterone replacement therapy approval. U.S. endocrinologists following the Endocrine Society guideline work from a 264 ng/dL harmonized lower limit and insist on repeated low morning values; urologists following the AUA use 300 ng/dL; and European guidelines (ISSAM, EAU, ESE/EAA) use 320 to 350 ng/dL. Anti-aging and men's health clinics often use more liberal criteria, sometimes treating men with testosterone levels around 400 ng/dL if symptoms persist. Insurance coverage generally requires strict adherence to established guidelines, with most plans covering treatment only when total testosterone falls below 300 ng/dL on multiple tests. Cash-pay clinics offer more flexibility but require careful consideration of cost-benefit ratios for 2026 treatment options. Some providers integrate complementary therapies like TB-500 or BPC-157 to support overall hormonal health alongside testosterone replacement therapy. These peptides may enhance recovery and well-being when used as part of full treatment protocols.

Guideline thresholds side by side: AUA 300, Endocrine Society 264, EAU and ISSAM 12.1 nmol/L, EAA 320

There is no single number. Each major guideline sets its own cutoff, and the differences explain most of the disagreement between clinics. Sources checked September 5, 2026.

Guideline	Total testosterone cutoff	Free testosterone	Testing rule
American Urological Association (2018, validity confirmed 2024)	Below 300 ng/dL (Statement 1, Grade B)	Used in the 230 to 317 ng/dL equivocal zone	Two measurements on separate early-morning occasions (Statement 2, Grade A)
Endocrine Society (2018)	Harmonized lower limit 264 ng/dL (9.2 nmol/L) for healthy non-obese young men; no 300 ng/dL cutoff	Measured when total is borderline or SHBG is abnormal	Fasting morning samples on separate days; values must be unequivocally and consistently low, plus symptoms
ISSAM	12.1 nmol/L (about 350 ng/dL)	225 pmol/L (65 pg/mL)	Morning sample, repeated
European Association of Urology	12.1 nmol/L (about 350 ng/dL)	243 pmol/L	Morning sample, repeated
European Society of Endocrinology and European Academy of Andrology	320 ng/dL (11 nmol/L)	64 pg/mL	Morning sample, repeated

The side-by-side comparison comes from Shin and Park's 2019 review in the Journal of Clinical Medicine (PMC6406807), which also notes that taking two or three morning measurements reduces within-person variability by 30 to 43 percent. Insurers in the U.S. most often write the AUA's 300 ng/dL into their policies; ask your plan which guideline it follows.

Why two tests: about 30 percent of low first results normalize on repeat

Every guideline in the table above requires a repeat test, and the reason is measured. Harvard Health reports that in about 30 percent of cases where a first testosterone test is low, the level is normal on repeat, and Shin and Park's review found that two or three morning draws cut intra-individual variability by 30 to 43 percent. Testosterone falls with illness, poor sleep, acute stress and time of day, so a single afternoon value can look like hypogonadism in a man who has none.

• Time of day: draw between about 7 and 11 a.m., when levels peak; the Endocrine Society and Alabama's medical board both specify fasting morning samples.
• Separate days: the AUA requires two separate early-morning occasions; the Endocrine Society requires separate days.
• Same lab, same assay: reference ranges differ by laboratory, and the Endocrine Society's 264 ng/dL figure is a harmonized value from CDC-standardized assays, not every lab's lower limit.
• What comes with the repeat: Alabama's February 2025 standard asks for a confirmatory fasting morning panel that includes total testosterone, LH, FSH, prolactin, hemoglobin and hematocrit, and PSA, which separates primary from secondary hypogonadism and screens for contraindications before a prescription.

Testosterone also declines about 2 percent a year from around age 40 (Harvard Health), so a man in his 50s with a level near the cutoff should expect the repeat to matter more, not less.

Ideal testosterone level on TRT: what the guidelines and one regulator actually say

Qualifying is one number; the target once you are treated is another, and it is lower than most forum advice. As of September 5, 2026:

Source	On-therapy target	Upper limit or stop rule
AUA (Statement 22)	Middle tertile of the normal reference range, defined as 450 to 600 ng/dL, which the guideline treats as therapeutic success	Recheck every 6 to 12 months (Statement 30)
Endocrine Society (2018)	Mid-normal range	Hematocrit above 54 percent defines erythrocytosis; withhold therapy
Alabama Board of Medical Examiners (approved February 20, 2025)	For injectables, level drawn mid-dose-interval should not exceed 700 ng/dL	Above 800 ng/dL considered excessive; labs every 6 months; annual in-person visit

The earlier statement on this page that optimal levels fall between 500 and 800 ng/dL was unsourced and has been replaced with these figures. A clinic that targets the top of the range, or above it, is outside every guideline listed here, and the hematocrit rule is the safety check that goes with the target: red cell mass rises with dose, and a hematocrit above 54 percent is the Endocrine Society's stop signal.

The 230 to 317 ng/dL equivocal zone and when free testosterone decides

The AUA guideline recognizes that a total testosterone between 230 and 317 ng/dL is equivocal, and it is in that band that free testosterone earns its place. Total testosterone counts hormone bound to SHBG, so a man with high SHBG (older age, liver disease, some medications) can have a low-normal total with a genuinely low free level, and a man with low SHBG (obesity, insulin resistance) can have the reverse.

Free testosterone cutoff	Guideline
64 pg/mL	European Society of Endocrinology and European Academy of Andrology
65 pg/mL (225 pmol/L)	ISSAM
243 pmol/L	European Association of Urology

An earlier version of this article used 50 pg/mL as a free testosterone threshold; that figure does not appear in any of the guidelines reviewed by Shin and Park (2019) and has been replaced. Two practical notes: free testosterone should be measured by equilibrium dialysis or calculated from total testosterone, SHBG and albumin, since direct analog assays are unreliable, and a low free level alone does not replace the symptom requirement in any guideline.

What a regulator's qualification checklist looks like: Alabama, February 2025

People asking what level qualifies for TRT with insurance or for approval are really asking what a reviewer will want to see. The Alabama Board of Medical Examiners published the most concrete public checklist we found, approved February 20, 2025. It governs Alabama prescribers, but it is a fair picture of what a careful clinic anywhere should document.

Step	Alabama requirement
Confirmatory labs	Fasting morning panel: total testosterone, LH, FSH, prolactin, hemoglobin and hematocrit, PSA
Contraindications to document	Cardiac event within the past 6 months, unmanaged obstructive sleep apnea, polycythemia, desire for fertility (testosterone suppresses sperm production)
Monitoring on injectables	Level drawn mid-dose-interval should not exceed 700 ng/dL; above 800 ng/dL is excessive
Follow-up	Labs every 6 months; an annual in-person visit, so telehealth alone is not acceptable in Alabama

Set that next to the guideline thresholds above and the qualifying picture is clear: two low fasting morning totals (below 300 ng/dL by the AUA rule, or below 264 ng/dL by the Endocrine Society's), symptoms, a panel that rules out a pituitary cause and screens for contraindications, and a monitoring plan before the first prescription. Telehealth clinics that skip any of those steps are the ones most likely to run into trouble with insurers and state boards.

Frequently Asked Questions

What is the ideal testosterone level on TRT?

Guidelines aim for the middle of the normal range, not the top. The AUA (2018, validity confirmed 2024) defines therapeutic success as the middle tertile of the reference range, about 450 to 600 ng/dL, rechecked every 6 to 12 months; the Endocrine Society targets the mid-normal range and withholds therapy if hematocrit exceeds 54 percent. Alabama's medical board says a mid-interval level on injections should not exceed 700 ng/dL, with values above 800 considered excessive.

Is 264 or 300 ng/dL the cutoff for low testosterone?

Both are published cutoffs from different bodies. The American Urological Association uses total testosterone below 300 ng/dL on two separate early-morning tests as a reasonable cutoff (Grade B). The Endocrine Society uses a harmonized lower limit of 264 ng/dL and requires consistently low fasting morning values on separate days. Most U.S. insurers write the 300 ng/dL figure into their policies; European guidelines use 320 to 350 ng/dL.

Do I need to fast before a testosterone test?

The Endocrine Society specifies fasting morning samples, and the Alabama Board of Medical Examiners' 2025 standard requires a fasting morning panel that includes total testosterone, LH, FSH, prolactin, hemoglobin and hematocrit, and PSA. Draw between about 7 and 11 a.m., repeat on a separate day, and use the same laboratory both times, because reference ranges differ between labs and about 30 percent of low first results are normal on repeat (Harvard Health).

Can I qualify for TRT with low free testosterone but normal total testosterone?

Sometimes. The AUA uses free testosterone when total testosterone falls in the equivocal 230 to 317 ng/dL band, and European guidelines set free testosterone cutoffs of 64 pg/mL (ESE/EAA) and about 65 pg/mL (ISSAM). Free testosterone should be calculated from total testosterone, SHBG and albumin or measured by equilibrium dialysis, and every guideline still requires symptoms and repeat morning testing. A prescriber, not a single lab value, makes the call.

Sources

1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364
2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. PMID: 29601923
3. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5-15. PMID: 25657080
4. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-4343. PMID: 16926258
5. Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men. J Clin Endocrinol Metab. 2010;95(4):1810-1818. PMID: 20173018
6. Antonio L, Wu FC, O'Neill TW, et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab. 2016;101(7):2647-2657. PMID: 27138356
7. Travison TG, Vesper HW, Orwoll E, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161-1173. PMID: 28324103
8. American Urological Association. Evaluation and management of testosterone deficiency: AUA guideline, 2018, validity confirmed 2024. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
9. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018;103(5):1715-1744 (PMID 29562364). https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy-in-men-with-hypogonadism
10. Shin YS, Park JK. The optimal indication for testosterone replacement therapy in late onset hypogonadism. J Clin Med 2019 (PMC6406807). https://pmc.ncbi.nlm.nih.gov/articles/PMC6406807/
11. Harvard Health Publishing. A new look at testosterone therapy, 2016. https://www.health.harvard.edu/mens-health/a-new-look-at-testosterone-therapy
12. Alabama Board of Medical Examiners. Guidelines for testosterone replacement therapy in males, approved February 20, 2025. https://www.albme.gov/uploads/pdfs/TRT_GuidelinesMale.pdf
13. Testosterone cypionate injection prescribing information (Cipla), DailyMed, revised 01/2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78d55bad-4a5b-4e21-aeb8-a4c6346208be